- Home
- BKYI vs TOVX Comparison
BKYI vs TOVX Comparison
Compare BKYI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- TOVX
- Stock Information
- Founded
- BKYI 1993
- TOVX 2001
- Country
- BKYI United States
- TOVX United States
- Employees
- BKYI N/A
- TOVX N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- TOVX Health Care
- Exchange
- BKYI Nasdaq
- TOVX Nasdaq
- Market Cap
- BKYI 3.5M
- TOVX 3.5M
- IPO Year
- BKYI 1997
- TOVX 2006
- Fundamental
- Price
- BKYI $0.92
- TOVX $1.18
- Analyst Decision
- BKYI
- TOVX Strong Buy
- Analyst Count
- BKYI 0
- TOVX 1
- Target Price
- BKYI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- BKYI 119.2K
- TOVX 97.3K
- Earning Date
- BKYI 11-14-2024
- TOVX 11-12-2024
- Dividend Yield
- BKYI N/A
- TOVX N/A
- EPS Growth
- BKYI N/A
- TOVX N/A
- EPS
- BKYI N/A
- TOVX N/A
- Revenue
- BKYI $7,292,394.00
- TOVX N/A
- Revenue This Year
- BKYI $1.96
- TOVX N/A
- Revenue Next Year
- BKYI $9.65
- TOVX N/A
- P/E Ratio
- BKYI N/A
- TOVX N/A
- Revenue Growth
- BKYI N/A
- TOVX N/A
- 52 Week Low
- BKYI $0.52
- TOVX $1.14
- 52 Week High
- BKYI $4.12
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- BKYI 41.70
- TOVX 38.15
- Support Level
- BKYI $0.85
- TOVX $1.23
- Resistance Level
- BKYI $1.00
- TOVX $1.34
- Average True Range (ATR)
- BKYI 0.11
- TOVX 0.08
- MACD
- BKYI -0.02
- TOVX 0.01
- Stochastic Oscillator
- BKYI 20.00
- TOVX 12.50
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.